Rho Kinase (ROCK) Inhibitors (e.g., Ripasudil, Netarsudil)

Type: drug

Status: Investigational (for corneal dystrophy)

Developer: Kowa Company, Aerie Pharmaceuticals

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026